276 related articles for article (PubMed ID: 31930360)
1. Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial.
Burgio KL; Kraus SR; Johnson TM; Markland AD; Vaughan CP; Li P; Redden DT; Goode PS
JAMA Intern Med; 2020 Mar; 180(3):411-419. PubMed ID: 31930360
[TBL] [Abstract][Full Text] [Related]
2. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.
Burgio KL; Goode PS; Johnson TM; Hammontree L; Ouslander JG; Markland AD; Colli J; Vaughan CP; Redden DT
J Am Geriatr Soc; 2011 Dec; 59(12):2209-16. PubMed ID: 22092152
[TBL] [Abstract][Full Text] [Related]
3. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
4. Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.
Pushkar DY; Kasyan GR; Kolontarev KB; Sharvadze GG; Mukhametshina EI
Neurourol Urodyn; 2019 Jun; 38(5):1313-1321. PubMed ID: 30888691
[TBL] [Abstract][Full Text] [Related]
5. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
Yüce T; Dökmeci F; Çetinkaya ŞE
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
[TBL] [Abstract][Full Text] [Related]
7. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
[TBL] [Abstract][Full Text] [Related]
8. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
[TBL] [Abstract][Full Text] [Related]
9. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
10. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial.
Burgio KL; Kraus SR; Menefee S; Borello-France D; Corton M; Johnson HW; Mallett V; Norton P; FitzGerald MP; Dandreo KJ; Richter HE; Rozanski T; Albo M; Zyczynski HM; Lemack GE; Chai TC; Khandwala S; Baker J; Brubaker L; Stoddard AM; Goode PS; Nielsen-Omeis B; Nager CW; Kenton K; Tennstedt SL; Kusek JW; Chang TD; Nyberg LM; Steers W;
Ann Intern Med; 2008 Aug; 149(3):161-9. PubMed ID: 18678843
[TBL] [Abstract][Full Text] [Related]
11. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
[TBL] [Abstract][Full Text] [Related]
12. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
13. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
[TBL] [Abstract][Full Text] [Related]
14. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
15. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
Staskin D; Herschorn S; Fialkov J; Tu LM; Walsh T; Schermer CR
Int Urogynecol J; 2018 Feb; 29(2):273-283. PubMed ID: 28620791
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
17. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
Rai BP; Cody JD; Alhasso A; Stewart L
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
[TBL] [Abstract][Full Text] [Related]
18. Effect of Behavioral and Pelvic Floor Muscle Therapy Combined With Surgery vs Surgery Alone on Incontinence Symptoms Among Women With Mixed Urinary Incontinence: The ESTEEM Randomized Clinical Trial.
Sung VW; Borello-France D; Newman DK; Richter HE; Lukacz ES; Moalli P; Weidner AC; Smith AL; Dunivan G; Ridgeway B; Nguyen JN; Mazloomdoost D; Carper B; Gantz MG;
JAMA; 2019 Sep; 322(11):1066-1076. PubMed ID: 31529007
[TBL] [Abstract][Full Text] [Related]
19. Structured behavioral treatment research protocol for women with mixed urinary incontinence and overactive bladder symptoms.
Newman DK; Borello-France D; Sung VW
Neurourol Urodyn; 2018 Jan; 37(1):14-26. PubMed ID: 28464426
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]